Electrochemiluminescence platform for the detection of C-reactive proteins: application of recombinant antibody technology to cardiac biomarker detection

Emmet J. O'Reilly, Paul J. Conroy, Stephen Hearty, Tia E. Keyes, Richard O'Kennedy, Robert J. Forster, Lynn Dennany

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

This work exploits the high-affinity of recombinant antibodies and low background electrochemiluminescence (ECL) for cardiac-biomarker detection. The developed assay is capable of fg mL-1 detection limits as well as the detection of C-Reactive Protein (CRP) over a clinically relevant range. The assay demonstrated robust reproducibility, selectivity and stability while also highlighting a novel platform for detection of cardiac biomarkers at low concentrations.
LanguageEnglish
Pages67874-67877
Number of pages4
JournalRSC Advances
Volume5
Issue number83
DOIs
Publication statusPublished - 31 Jul 2015

Fingerprint

Biomarkers
Antibodies
C-Reactive Protein
Assays
Proteins

Keywords

  • recombinant antibodies
  • cardiac biomarkers
  • c-reactive proteins

Cite this

O'Reilly, Emmet J. ; Conroy, Paul J. ; Hearty, Stephen ; Keyes, Tia E. ; O'Kennedy, Richard ; Forster, Robert J. ; Dennany, Lynn. / Electrochemiluminescence platform for the detection of C-reactive proteins : application of recombinant antibody technology to cardiac biomarker detection. In: RSC Advances. 2015 ; Vol. 5, No. 83. pp. 67874-67877.
@article{5312fd0934514ad6a774841dd8861fb8,
title = "Electrochemiluminescence platform for the detection of C-reactive proteins: application of recombinant antibody technology to cardiac biomarker detection",
abstract = "This work exploits the high-affinity of recombinant antibodies and low background electrochemiluminescence (ECL) for cardiac-biomarker detection. The developed assay is capable of fg mL-1 detection limits as well as the detection of C-Reactive Protein (CRP) over a clinically relevant range. The assay demonstrated robust reproducibility, selectivity and stability while also highlighting a novel platform for detection of cardiac biomarkers at low concentrations.",
keywords = "recombinant antibodies, cardiac biomarkers, c-reactive proteins",
author = "O'Reilly, {Emmet J.} and Conroy, {Paul J.} and Stephen Hearty and Keyes, {Tia E.} and Richard O'Kennedy and Forster, {Robert J.} and Lynn Dennany",
year = "2015",
month = "7",
day = "31",
doi = "10.1039/C5RA08450D",
language = "English",
volume = "5",
pages = "67874--67877",
journal = "RSC Advances",
issn = "2046-2069",
number = "83",

}

Electrochemiluminescence platform for the detection of C-reactive proteins : application of recombinant antibody technology to cardiac biomarker detection. / O'Reilly, Emmet J.; Conroy, Paul J.; Hearty, Stephen; Keyes, Tia E.; O'Kennedy, Richard; Forster, Robert J.; Dennany, Lynn.

In: RSC Advances, Vol. 5, No. 83, 31.07.2015, p. 67874-67877.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Electrochemiluminescence platform for the detection of C-reactive proteins

T2 - RSC Advances

AU - O'Reilly, Emmet J.

AU - Conroy, Paul J.

AU - Hearty, Stephen

AU - Keyes, Tia E.

AU - O'Kennedy, Richard

AU - Forster, Robert J.

AU - Dennany, Lynn

PY - 2015/7/31

Y1 - 2015/7/31

N2 - This work exploits the high-affinity of recombinant antibodies and low background electrochemiluminescence (ECL) for cardiac-biomarker detection. The developed assay is capable of fg mL-1 detection limits as well as the detection of C-Reactive Protein (CRP) over a clinically relevant range. The assay demonstrated robust reproducibility, selectivity and stability while also highlighting a novel platform for detection of cardiac biomarkers at low concentrations.

AB - This work exploits the high-affinity of recombinant antibodies and low background electrochemiluminescence (ECL) for cardiac-biomarker detection. The developed assay is capable of fg mL-1 detection limits as well as the detection of C-Reactive Protein (CRP) over a clinically relevant range. The assay demonstrated robust reproducibility, selectivity and stability while also highlighting a novel platform for detection of cardiac biomarkers at low concentrations.

KW - recombinant antibodies

KW - cardiac biomarkers

KW - c-reactive proteins

U2 - 10.1039/C5RA08450D

DO - 10.1039/C5RA08450D

M3 - Article

VL - 5

SP - 67874

EP - 67877

JO - RSC Advances

JF - RSC Advances

SN - 2046-2069

IS - 83

ER -